Holen Sie sich die Stockscreener-App
14.60
5.19%
0.72
Handel nachbörslich:
14.60
Schlusskurs vom Vortag:
$13.88
Offen:
$13.7
24-Stunden-Volumen:
236.70K
Relative Volume:
3.06
Marktkapitalisierung:
$211.35M
Einnahmen:
$1.80M
Nettoeinkommen (Verlust:
$-241.36M
KGV:
-3.6049
EPS:
-4.05
Netto-Cashflow:
$-197.90M
1W Leistung:
-0.14%
1M Leistung:
+3.99%
6M Leistung:
+0.76%
1J Leistung:
-49.72%
1-Tages-Spanne:
$13.51
$14.72
1-Wochen-Bereich:
$13.51
$15.24
52-Wochen-Spanne:
$10.80
$39.79
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Vergleichen Sie INBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
14.60 | 211.35M | 1.80M | -241.36M | -197.90M | -5.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
How To Trade (INBX) - Stock Traders Daily
(INBX) Trading Report - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria
Trend Tracker for (INBX) - Stock Traders Daily
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com
Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire
Inhibrx Q3 Loss Narrows to $2.84/Share, Maintains $196M Cash for Clinical Programs - StockTitan
Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle
(INBX) Trading Signals - Stock Traders Daily
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times
James Sabry on industry-shaping changes in innovation and deal-making - BioCentury
Long Term Trading Analysis for (INBX) - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year - Investing.com Australia
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year By Investing.com - Investing.com South Africa
why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News
INVX underperforms with a -2.86 decrease in share price - US Post News
You might want to take a look at Imunon Inc (IMNN) now - SETE News
Immuneering Corp [IMRX] Shares Fall Approximately -71.25% Over the Year - Knox Daily
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World
Incyte (NASDAQ:INCY) Given “Hold” Rating at Truist Financial - Defense World
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Down 6.9% in August - Defense World
InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World
William Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com
A review of IMNN’s current quarter earnings predictions - US Post News
Its Stock Has Paid Off Big Time For INmune Bio Inc - SETE News
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
IBRX Stock on the Rise: A Promising Investment - The InvestChronicle
Market Watch: Immuneering Corp (IMRX)’s Noteworthy Drop, Closing at 2.78 - The Dwinnex
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
Incyte (NASDAQ:INCY) Receives Market Perform Rating from JMP Securities - Defense World
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
Ratio Review: Analyzing Innovex International Inc. (INVX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
10% Owner Of Impinj Makes $20.00M Buy - Benzinga
Inmune Bio CFO acquires $49k in company stock By Investing.com - Investing.com Canada
Inmune Bio CEO acquires $98k in company stock - Investing.com
Inmune Bio CFO buys $49k in company stock - Investing.com
Inhibrx CEO buys shares worth over $629k - Investing.com India
Inhibrx CEO buys shares worth over $629k By Investing.com - Investing.com Canada
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
How will ImmunityBio Inc’s (IBRX) earnings compare to estimates this quarter? - US Post News
What is IMRX’s price-to-sales ratio telling us about the company’s value? - US Post News
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inhibrx Biosciences Inc-Aktie (INBX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kayyem Jon Faiz | Director |
Nov 20 '24 |
Buy |
14.19 |
37,500 |
532,204 |
69,843 |
| Lappe Mark | Chief Executive Officer |
Sep 12 '24 |
Buy |
15.05 |
26,963 |
405,793 |
692,511 |
| Lappe Mark | Chief Executive Officer |
Sep 16 '24 |
Buy |
17.13 |
13,037 |
223,324 |
705,548 |
| Vuori Kristiina MD | Director |
Sep 11 '24 |
Buy |
15.07 |
6,457 |
97,307 |
13,776 |
| Vuori Kristiina MD | Director |
Sep 10 '24 |
Buy |
15.00 |
179 |
2,685 |
7,319 |
| Lappe Mark | Chief Executive Officer |
Sep 06 '24 |
Buy |
15.29 |
26,000 |
397,540 |
647,548 |
| Lappe Mark | Chief Executive Officer |
Sep 09 '24 |
Buy |
15.21 |
9,500 |
144,495 |
657,048 |
| Lappe Mark | Chief Executive Officer |
Sep 10 '24 |
Buy |
15.19 |
8,500 |
129,115 |
665,548 |
| Lappe Mark | Chief Executive Officer |
Sep 03 '24 |
Buy |
15.81 |
20,000 |
316,263 |
165,000 |
| Lappe Mark | Chief Executive Officer |
Aug 29 '24 |
Buy |
14.03 |
10,000 |
140,300 |
135,000 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):